Research & Development
Jacobio's JAB-2485 IND application receives US FDA approval
17 January 2022 -

Jacobio, a China-based clinical-stage pharmaceutical company, announced on Sunday that it has received Investigational New Drug (IND) approval from the Food and Drug Administration (FDA) in the United States for the company's self-developed global first-in-class drug Aurora A inhibitor JAB-2485.

The company is planning to start a Phase I/IIa clinical trial in patients with advanced solid tumours in the United States.

The product is a highly selective small molecule Aurora A inhibitor that can inhibit Aurora A activity at the cellular level, induce apoptosis and inhibit tumour growth. The inhibitory activity of Aurora A is one thousand times higher than that of Aurora B, and has potential to benefit patients with small cell lung cancer and triple negative breast cancer.

The company's self-developed JAB-2485 is the third Aurora A inhibitor enter into clinical stage in the United States.



Related Headlines